Global Medical REIT faces significant structural headwinds as evidenced by a collapse in FFO per share from $6.58 in 2025Q1 to $0.28 in 2025Q4. The company's reliance on external financing to cover capital expenditures, which surged to $105.1M in 2025Q4, creates a precarious liquidity profile that threatens long-term…
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 25, 2026 | $1.10+1592.3% vs $0.07 | $35M-6.1% vs $37M |
Q4 2025 Nov 4, 2025 | -$0.45-381.3% vs $0.16 | $37M-3.0% vs $38M |
Q3 2025 Aug 5, 2025 | -$0.05-250.0% vs $0.03 | $38M+7.2% vs $35M |
Q2 2025 May 7, 2025 | $0.79+1480.0% vs $0.05 | $35M-1.7% vs $35M |
Chiron Real Estate reported second-quarter results as it continues to reposition its portfolio toward senior housing and away from outpatient medical real estate, with management emphasizing capital recycling, leadership additions and a growing investment pipeline. Chief Executive Officer Mark Decker Jr. said the company's existing portfolio remained operationally stable while it pursued a broader strategic
Benchmark XRN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Chiron Real Estate Inc. (XRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.70 | $379.92M | 7.09 | 16.34% | 34.26% | 8.88% | 13.62% | |
| $14.71 | $420.29M | 17.77 | 4.67% | 17.8% | 5.34% | 13.58% | |
| $16.26 | $413.2M | -11.18 | -3.24% | -14.48% | -14.03% | 12.96% | |
| $19.20 | $6.73B | -145.56 | -6.92% | -3.96% | -1.02% | 5.76% | |
| $20.26 | $13.97B | 35.99 | 4.52% | 12.66% | 4.13% | 6.02% | |
| $1.81 | $1.08B | 4.34 | -2.36% | 24.14% | 5.45% | 17.77% |
Chiron Real Estate Inc. (XRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Chiron Real Estate Inc. (XRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 5, 2026·SEC
Aug 5, 2026·SEC
Get notified when XRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Chiron Real Estate Inc. (XRN) stock FAQ — growth, dividends, profitability & financials explained
Chiron Real Estate Inc. (XRN) reported $156.5M in revenue over the trailing twelve months. Revenue was $161.0M in fiscal year 2025.
Chiron Real Estate Inc. (XRN) grew revenue by 1.2% over the trailing twelve months, compared with the twelve months before.
Yes. Chiron Real Estate Inc. (XRN) earned $53.6M in net income over the trailing twelve months (a 34.3% net margin).
Yes. Chiron Real Estate Inc. (XRN) pays a dividend that yields 13.62% at the current price, a high yield.
Chiron Real Estate Inc. (XRN) had a return on equity (ROE) of 8.9% over the trailing twelve months. That is below the market's typical 10-15%.
Chiron Real Estate Inc. (XRN) had negative free cash flow of $188.6M over the trailing twelve months.
